According to a statement from Emergent BioSolutions Inc. (EBS) and a letter from the U.S. Food and Drug Administration (FDA) seen by The Wall Street Journal, after obtaining FDA approval, Emergent intends to resume production of the new crown vaccine at the Baltimore plant.
“After conducting additional evaluations and cooperation with the FDA and our production partners, we are very honored to be able to resume mass production of the new crown vaccine.” Emergent CEO Robert Kramer said in a statement Wednesday evening. “We are grateful for the opportunity to help end this global epidemic.”
The plant produces vaccines for Johnson & Johnson (JNJ).
In recent months, although the domestic demand for Johnson & Johnson vaccines in the United States has decreased, Biden (Joe…
.